About 25% of healthcare spending goes towards administrative costs, largely due to issues with fragmented systems. This is what Yuzu Health, a third-party administrator, aims to solve, announcing on ...

Cadence raised $100 million in Series C funding to scale its AI-powered chronic care platform, which monitors patients at ...

This week, Neurovalens‘ Modius Spero became the first neuromodulation device to earn FDA approval to treat PTSD. Veterans, who face disproportionately high PTSD rates, will be the first to gain access ...

Roche is a relative latecomer in the chase to block a protein called KRAS G12C to treat lung cancer, but the pharmaceutical company has been testing its contender head-to-head against approved ...

Anthropic is rolling out Claude Science, an AI workbench for pharma researchers. The buzzy AI startup says this new product goes beyond assisting scientists to actually doing their work. “Claude can ...

American healthcare spending has surpassed $5 trillion annually and continues to rise faster than inflation and wages: hospitals warn of financial distress, primary care says it is underfunded, rural ...

Medicare is about to launch an experiment of historic scale. Beginning in July, seniors with a diagnosis of obesity will be able to access GLP-1 medications with a $50 co-pay through the Bridge ...

In the leadup to the FDA decision for Cytokinetics’s obstructive hypertrophic cardiomyopathy drug, the outstanding question wasn’t so much whether the agency would approve the medication, but rather ...

Ounce, a startup that aims to “bridge the gap” between health and housing, announced Thursday that it has secured $5.2 million in seed funding. In addition, the company announced its first set of ...

This week, Epic hosted its annual Users Group Meeting, a multi-day gathering that brought together thousands of healthcare leaders at the EHR giant’s headquarters in Verona, Wisconsin. During the ...

As a Sanofi veteran, Frédéric Marrache is well aware of the innovations shaping immunology. His tenure there came as Dupixent grew into the company’s top-selling product, now spanning nine ...

A metabolic disorder that leads to high levels of fat in the blood and life-threatening pancreatic complications now has its first FDA-approved medicine, an RNA-targeting therapy developed by Ionis ...